These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 23644347)

  • 1. Controlled delivery of naltrexone by an intraoral device: in vivo study on human subjects.
    Paderni C; Campisi G; Schumacher A; Göttsche T; Giannola LI; De Caro V; Wolff A
    Int J Pharm; 2013 Aug; 452(1-2):128-34. PubMed ID: 23644347
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bioavailability in vivo of naltrexone following transbuccal administration by an electronically-controlled intraoral device: a trial on pigs.
    Campisi G; Giannola LI; Florena AM; De Caro V; Schumacher A; Göttsche T; Paderni C; Wolff A
    J Control Release; 2010 Aug; 145(3):214-20. PubMed ID: 20438777
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Release of naltrexone on buccal mucosa: permeation studies, histological aspects and matrix system design.
    Giannola LI; De Caro V; Giandalia G; Siragusa MG; Tripodo C; Florena AM; Campisi G
    Eur J Pharm Biopharm; 2007 Sep; 67(2):425-33. PubMed ID: 17451927
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relative oral bioavailability of morphine and naltrexone derived from crushed morphine sulfate and naltrexone hydrochloride extended-release capsules versus intact product and versus naltrexone solution: a single-dose, randomized-sequence, open-label, three-way crossover trial in healthy volunteers.
    Johnson FK; Stark JG; Bieberdorf FA; Stauffer J
    Clin Ther; 2010 Jun; 32(6):1149-64. PubMed ID: 20637968
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New prospectives in the delivery of galantamine for elderly patients using the IntelliDrug intraoral device: in vivo animal studies.
    Giannola LI; Paderni C; De Caro V; Florena AM; Wolff A; Campisi G
    Curr Pharm Des; 2010; 16(6):653-9. PubMed ID: 20388075
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single- and multiple-dose pharmacokinetics of long-acting injectable naltrexone.
    Dunbar JL; Turncliff RZ; Dong Q; Silverman BL; Ehrich EW; Lasseter KC
    Alcohol Clin Exp Res; 2006 Mar; 30(3):480-90. PubMed ID: 16499489
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of long-acting naltrexone in subjects with mild to moderate hepatic impairment.
    Turncliff RZ; Dunbar JL; Dong Q; Silverman BL; Ehrich EW; Dilzer SC; Lasseter KC
    J Clin Pharmacol; 2005 Nov; 45(11):1259-67. PubMed ID: 16239359
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diffusion of naltrexone across reconstituted human oral epithelium and histomorphological features.
    Giannola LI; De Caro V; Giandalia G; Siragusa MG; Campisi G; Florena AM; Ciach T
    Eur J Pharm Biopharm; 2007 Feb; 65(2):238-46. PubMed ID: 16962298
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of alcohol on the pharmacokinetics of morphine sulfate and naltrexone hydrochloride extended release capsules.
    Johnson FK; Ciric S; Boudriau S; Kisicki J; Stauffer J
    J Clin Pharmacol; 2012 May; 52(5):747-56. PubMed ID: 21593282
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improving clinical outcomes in treating heroin dependence: randomized, controlled trial of oral or implant naltrexone.
    Hulse GK; Morris N; Arnold-Reed D; Tait RJ
    Arch Gen Psychiatry; 2009 Oct; 66(10):1108-15. PubMed ID: 19805701
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics, safety, and tolerability of a depot formulation of naltrexone in alcoholics: an open-label trial.
    Galloway GP; Koch M; Cello R; Smith DE
    BMC Psychiatry; 2005 Apr; 5():18. PubMed ID: 15804355
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative bioavailability study of a generic naltrexone tablet preparation.
    Yuen KH; Peh KK; Billa N
    Drug Dev Ind Pharm; 1999 Mar; 25(3):353-6. PubMed ID: 10071829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sustained-release naltrexone for alcoholism treatment: a preliminary study.
    Kranzler HR; Modesto-Lowe V; Nuwayser ES
    Alcohol Clin Exp Res; 1998 Aug; 22(5):1074-9. PubMed ID: 9726277
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Achieving long-term continuous blood naltrexone and 6-beta-naltrexol coverage following sequential naltrexone implants.
    Hulse GK; Arnold-Reed DE; O'Neil G; Chan CT; Hansson RC
    Addict Biol; 2004 Mar; 9(1):67-72. PubMed ID: 15203441
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk factors for craving and relapse in heroin users treated with oral or implant naltrexone.
    Hulse GK; Ngo HT; Tait RJ
    Biol Psychiatry; 2010 Aug; 68(3):296-302. PubMed ID: 20537615
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose proportionality and the effects of food on bioavailability of an immediate-release oxycodone hydrochloride tablet designed to discourage tampering and its relative bioavailability compared with a marketed oxycodone tablet under fed conditions: a single-dose, randomized, open-label, 5-way crossover study in healthy volunteers.
    Bass A; Stark JG; Pixton GC; Sommerville KW; Zamora CA; Leibowitz M; Rolleri R
    Clin Ther; 2012 Jul; 34(7):1601-12. PubMed ID: 22717418
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Open-label pilot study of extended-release naltrexone to reduce drinking and driving among repeat offenders.
    Lapham SC; McMillan GP
    J Addict Med; 2011 Sep; 5(3):163-9. PubMed ID: 21844831
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vivitrex (Alkermes/Cephalon).
    Heading CE
    Curr Opin Investig Drugs; 2006 Jan; 7(1):81-8. PubMed ID: 16425675
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I study of injectable, depot naltrexone for the relapse prevention treatment of opioid dependence.
    Xuyi W; Juelu W; Xiaojun X; Haiyan L; Zheyuan L; Zhehui G; Guoming D; Gang L; Jin L; Wei H
    Am J Addict; 2014; 23(2):162-9. PubMed ID: 24107112
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blood naltrexone and 6-beta-naltrexol levels following naltrexone implant: comparing two naltrexone implants.
    Hulse GK; Arnold-Reed DE; O'Neil G; Chan CT; Hansson R; O'Neil P
    Addict Biol; 2004 Mar; 9(1):59-65. PubMed ID: 15203440
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.